Switzerland fast-tracks antiviral medication against Covid-19
Remdesivir has already been granted temporary approval in other countries.
Keystone / Marcel Kusch
The Swiss health authorities have granted approval for the remdesivir drug in “record time” for treating coronavirus patients. The temporary authorisation to widen the use of the antiviral drug will be closely monitored in case of adverse side effects.
This content was published on
2 minutes
swissinfo.ch/mga
Swissmedic, the agency that oversees the use of medicaments in Switzerland, took days to fast-track approval of the drug, which is produced under the brand name Veklury by US biopharmaceutical company Gilead Sciences. The application for its extended use was only received on Monday.
It can now be used for a limited period of time to treat patients suffering from SARS-CoV-2-related pneumonia who also require oxygen.
The drug has been authorized for emergency use in the United States, India, Singapore, South Korea and Japan and has been recommended by the European Medicines Agency to treat coronavirus patients in the EU.
Swissmedic said on Thursday that it had conducted a “careful review in record time” of the drug. Hospital doctors have now been given the green light to administer the treatment. “Adverse reactions to the drug will be closely monitored in order to ensure patient safety,” read a statement.
“The product will also be made available to patients outside approved clinical trials and the approved compassionate use programme while the submitted authorisation application is being reviewed,” it added.
Clinical trials in the US on medicaments containing the active ingredient remdesivir found that the hospital stay of severely affected Covid-19 patients was shortened in almost a third of cases.
Related Stories
Popular Stories
More
International Geneva
A Geneva-based global health foundation came close to ‘collapse’. Where were regulators?
Swiss-EU treaties: signatures handed in for Kompass initiative
This content was published on
The committee behind the Compass Initiative submitted the signatures it had collected to the Federal Chancellery on Friday.
This content was published on
Esther Grether has died aged 89. Considered one of Switzerland’s leading entrepreneurs, the owner of the Basel-based Doetsch Grether Group was also a major shareholder in the Swatch Group and an art collector.
This content was published on
The flag of the Swiss Wrestling Federation has been received at the start of the Swiss Wrestling and Alpine Festival in Mollis, canton Glarus.
Figurine heads in Zurich school not considered discriminatory
This content was published on
The 16 carved figurine heads in the auditorium of the Hirschengraben school building in Zurich are not discriminatory, according to an independent expert report.
Swiss political parties report income of CHF22.4 million for 2024
This content was published on
Ten parties reported income totalling CHF22.4 million for 2024, less than in the 2023 election year. The reports are based on the regulations for transparency in political financing.
FIFA loses multi-million lawsuit against Blatter and Kattner
This content was published on
Former FIFA officials Joseph Blatter and Markus Kattner do not have to pay back their own bonuses or the bonus totalling CHF 23 million paid to another FIFA official to FIFA. This was decided by the Zurich Labour Court.
How cancer cells makes healthy cells work for them
This content was published on
Cancer cells manipulate neighbouring cells for their own purposes: a research team at ETH Zurich has discovered that they can reprogram neighbouring cells in such a way that they help the tumour to grow.
This content was published on
The ban on non-residents entering the swimming pool in Porrentruy, canton Jura, expires on Sunday and would be extended until the end of the season, the mayor said.
Natural disasters: most Swiss back forced resettlement
This content was published on
The authorities should be allowed to order forced relocations if there is a medium-term risk of a natural event, according to 58% of participants in a survey.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Sixteen Swiss hospitals take part in coronavirus global Solidarity trial
This content was published on
Some 1,000 patients in Switzerland are expected to participate in trials of experimental treatments for Covid-19 as part of global Solidarity trial.
Fight over rights to Covid-19 drugs puts Switzerland in a tough spot
This content was published on
As calls mount for equitable access, Switzerland is caught between established practice and global solidarity in how to encourage medical innovation.
This content was published on
Swiss scientists and drug companies are playing an important role in the global effort to develop treatments or a vaccine for the virus.
Swiss hospitals launch drug trial to prevent Covid-19 infection
This content was published on
Researchers in Geneva and Basel have launched a clinical trial to test two drugs on people that have been in contact with Covid-19 patients.
Novartis steps up coronavirus fight as part of new collaboration
This content was published on
Several big pharmaceutical companies have joined forces with the Bill & Melinda Gates Foundation in response to the coronavirus pandemic.
Balancing hope and science in the search for a coronavirus cure
This content was published on
The debate surrounding the antimalarial drug hydroxychloroquine epitomises companies' balancing act between hope and scientific realities.
Covid-19 is both threat and opportunity for Swiss biotech
This content was published on
Although the coronavirus pandemic is the Swiss biotech industry’s time to shine, it has left many smaller firms struggling to survive.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.